Polycythemia Vera | Treatment Algorithms: Claims Data Analysis | US | 2020
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PV patients?
- How has ruxolitinib (Jakafi) been integrated into the treatment algorithm and what is its source of business?
- What percentage of PV patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after the diagnosis?
- What percentage of PV patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Bristol Myers Squibb, Incyte, Roche, Merck
Key drugs: Hydroxyurea, ruxolitinib (Jakafi), interferons, antiplatelet therapies
Related Market Assessment Reports
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
